Feed / BCRX

BioCryst Pharmaceuticals, Inc.

BCRX

Healthcare · 9.85 +1.8% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

BioCryst Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

What changed
  • Revenue increased 33.6% versus the comparable filing period.
Company+1.8% todayVolume comparison unavailable
Market group0 of 1 activeHereditary Angioedema Drugs · unavailable
Disclosed network0 of 6 confirmingNo filing-linked name is confirming now
What would change this read
  • Reported $25.6M increase in ORLADEYO revenue (ex-Europe) attributed to increased direct sales and a net price increase; track future revenue and stated demand/price drivers.

Invalidation: The isolated read changes if BCRX's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind BCRX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CLSDQFiling-linked namepartnerFeb 26, 2026

Avoralstat We are developing our investigational plasma kallikrein inhibitor, avoralstat, with Clearside Biomedical, Inc.’s SCS Microinjector ® to deliver avoralstat to the back of the eye through the suprachoroidal space to treat patients with diabetic macul…

SGIOFFiling-linked namepartnerFeb 26, 2026

In January 2010, our partner, Shionogi, received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA.

NBRGFiling-linked namepartnerFeb 26, 2026

In 2021, we entered into supply and distribution agreements with Neopharm Ltd.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BCRX is currently a Leader in the organic co-movement group Hereditary Angioedema Drugs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for BCRX; it is not active in the latest market snapshot.